Features include always present findings: Microcephaly, Delayed speech and language development, Brachydactyly, and Delayed ability to walk and others; and common findings: Absent speech, Inability to walk, Seizure, and Gait ataxia.

DCPS encodes decapping enzyme, scavenger (337 aa). Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Highest expression in Cells EBV-transformed lymphocytes (83.9 TPM) and Liver (43.7 TPM).

Al-Raqad syndrome is associated with mutations in the DCPS gene on chromosome 11.

DCPS is classified as a druggable target (Druggable Genome and Enzyme categories) with score 104.4.

Genetic testing for DCPS is available. Testing is considered confirmatory for diagnosis.

Phenotype severity distribution: 18 always present features, 4 common features.

No clinical trials have been registered for Al-Raqad syndrome.

4 publications have been identified in PubMed for Al-Raqad syndrome. Research spans Case Report / Case Series (50%) and Basic Science / Preclinical (50%).

Recent Publications

• Ferenc-Mrozek A (2026). [PMID: 42204260](https://pubmed.ncbi.nlm.nih.gov/42204260/). *Sci Rep*. [Basic Science / Preclinical]

• Nozaki H (2025). [PMID: 40344930](https://pubmed.ncbi.nlm.nih.gov/40344930/). *Brain Dev*. [Case Report / Case Series]

• Yang J (2025). [PMID: 40410278](https://pubmed.ncbi.nlm.nih.gov/40410278/). *Sci Rep*. [Basic Science / Preclinical]

• Crespin M (2025). [PMID: 39420558](https://pubmed.ncbi.nlm.nih.gov/39420558/). *HGG Adv*. [Case Report / Case Series]